炎症性腸疾患(Inflammatory Bowel Disease):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Inflammatory Bowel Disease - Pipeline Review, H2 2014
◆商品コード:GMDHC5677IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:350
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における炎症性腸疾患(Inflammatory Bowel Disease)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・炎症性腸疾患(Inflammatory Bowel Disease)の概要
・炎症性腸疾患(Inflammatory Bowel Disease)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・炎症性腸疾患(Inflammatory Bowel Disease)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・炎症性腸疾患(Inflammatory Bowel Disease)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・炎症性腸疾患(Inflammatory Bowel Disease)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Inflammatory Bowel Disease – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Inflammatory Bowel Disease – Pipeline Review, H2 2014’, provides an overview of the Inflammatory Bowel Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Inflammatory Bowel Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Inflammatory Bowel Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Inflammatory Bowel Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 7
Inflammatory Bowel Disease Overview 8
Therapeutics Development 9
Inflammatory Bowel Disease – Therapeutics under Development by Companies 11
Inflammatory Bowel Disease – Therapeutics under Investigation by Universities/Institutes 19
Inflammatory Bowel Disease – Pipeline Products Glance 21
Inflammatory Bowel Disease – Products under Development by Companies 24
Inflammatory Bowel Disease – Products under Investigation by Universities/Institutes 32
Inflammatory Bowel Disease – Companies Involved in Therapeutics Development 33
Inflammatory Bowel Disease – Therapeutics Assessment 108
Drug Profiles 122
Inflammatory Bowel Disease – Recent Pipeline Updates 289
Inflammatory Bowel Disease – Dormant Projects 317
Inflammatory Bowel Disease – Discontinued Products 326
Inflammatory Bowel Disease – Product Development Milestones 327
Appendix 334

[List of Tables]
Number of Products under Development for Inflammatory Bowel Disease, H2 2014 24
Number of Products under Development for Inflammatory Bowel Disease - Comparative Analysis, H2 2014 25
Number of Products under Development by Companies, H2 2014 27
Number of Products under Development by Companies, H2 2014 (Contd..1) 28
Number of Products under Development by Companies, H2 2014 (Contd..2) 29
Number of Products under Development by Companies, H2 2014 (Contd..3) 30
Number of Products under Development by Companies, H2 2014 (Contd..4) 31
Number of Products under Development by Companies, H2 2014 (Contd..5) 32
Number of Products under Development by Companies, H2 2014 (Contd..6) 33
Number of Products under Investigation by Universities/Institutes, H2 2014 35
Comparative Analysis by Clinical Stage Development, H2 2014 36
Comparative Analysis by Early Stage Development, H2 2014 37
Comparative Analysis by Unknown Stage Development, H2 2014 38
Products under Development by Companies, H2 2014 39
Products under Development by Companies, H2 2014 (Contd..1) 40
Products under Development by Companies, H2 2014 (Contd..2) 41
Products under Development by Companies, H2 2014 (Contd..3) 42
Products under Development by Companies, H2 2014 (Contd..4) 43
Products under Development by Companies, H2 2014 (Contd..5) 44
Products under Development by Companies, H2 2014 (Contd..6) 45
Products under Development by Companies, H2 2014 (Contd..7) 46
Products under Investigation by Universities/Institutes, H2 2014 47
Inflammatory Bowel Disease - Pipeline by 4SC AG, H2 2014 48
Inflammatory Bowel Disease - Pipeline by ActogeniX NV, H2 2014 49
Inflammatory Bowel Disease - Pipeline by Addex Therapeutics Ltd, H2 2014 50
Inflammatory Bowel Disease - Pipeline by Advinus Therapeutics Ltd., H2 2014 51
Inflammatory Bowel Disease - Pipeline by Aerpio Therapeutics, Inc., H2 2014 52
Inflammatory Bowel Disease - Pipeline by AlbireoPharma, H2 2014 53
Inflammatory Bowel Disease - Pipeline by Am-Pharma B.V., H2 2014 54
Inflammatory Bowel Disease - Pipeline by Amakem NV, H2 2014 55
Inflammatory Bowel Disease - Pipeline by Amgen Inc., H2 2014 56
Inflammatory Bowel Disease - Pipeline by Amorepacific Corporation, H2 2014 57
Inflammatory Bowel Disease - Pipeline by Aquinox Pharmaceuticals Inc., H2 2014 58
Inflammatory Bowel Disease - Pipeline by Ardelyx, Inc., H2 2014 59
Inflammatory Bowel Disease - Pipeline by Argos Therapeutics, Inc., H2 2014 60
Inflammatory Bowel Disease - Pipeline by ASKA Pharmaceutical Co., Ltd., H2 2014 61
Inflammatory Bowel Disease - Pipeline by Axxam SpA, H2 2014 62
Inflammatory Bowel Disease - Pipeline by Basilea Pharmaceutica AG, H2 2014 63
Inflammatory Bowel Disease - Pipeline by BioLineRx, Ltd., H2 2014 64
Inflammatory Bowel Disease - Pipeline by Biotec Pharmacon ASA, H2 2014 65
Inflammatory Bowel Disease - Pipeline by BioTherapeutics Inc., H2 2014 66
Inflammatory Bowel Disease - Pipeline by Blueberry Therapeutics Ltd, H2 2014 67
Inflammatory Bowel Disease - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2014 68
Inflammatory Bowel Disease - Pipeline by Celsus Therapeutics Plc, H2 2014 69
Inflammatory Bowel Disease - Pipeline by ChemoCentryx, Inc., H2 2014 70
Inflammatory Bowel Disease - Pipeline by ChironWells GmbH, H2 2014 71
Inflammatory Bowel Disease - Pipeline by Compugen Ltd., H2 2014 72
Inflammatory Bowel Disease - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2014 73
Inflammatory Bowel Disease - Pipeline by Creabilis SA, H2 2014 74
Inflammatory Bowel Disease - Pipeline by Delenex Therapeutics AG, H2 2014 75
Inflammatory Bowel Disease - Pipeline by Eisai Co., Ltd., H2 2014 76
Inflammatory Bowel Disease - Pipeline by Emergent BioSolutions Inc., H2 2014 77
Inflammatory Bowel Disease - Pipeline by Galapagos NV, H2 2014 78
Inflammatory Bowel Disease - Pipeline by Genentech, Inc., H2 2014 79
Inflammatory Bowel Disease - Pipeline by Genfit SA, H2 2014 80
Inflammatory Bowel Disease - Pipeline by GlaxoSmithKline plc, H2 2014 81
Inflammatory Bowel Disease - Pipeline by GlycoMar Limited, H2 2014 82
Inflammatory Bowel Disease - Pipeline by iCo Therapeutics Inc., H2 2014 83
Inflammatory Bowel Disease - Pipeline by Inotek Pharmaceuticals Corporation, H2 2014 84
Inflammatory Bowel Disease - Pipeline by Janssen Biotech, Inc., H2 2014 85
Inflammatory Bowel Disease - Pipeline by Kineta, Inc., H2 2014 86
Inflammatory Bowel Disease - Pipeline by Kymab Limited, H2 2014 87
Inflammatory Bowel Disease - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2014 88
Inflammatory Bowel Disease - Pipeline by Kytogenics Pharmaceuticals, Inc., H2 2014 89
Inflammatory Bowel Disease - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2014 90
Inflammatory Bowel Disease - Pipeline by Lycera Corp., H2 2014 91
Inflammatory Bowel Disease - Pipeline by Medestea Research & Production S.p.A., H2 2014 92
Inflammatory Bowel Disease - Pipeline by Medgenics Inc., H2 2014 93
Inflammatory Bowel Disease - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 94
Inflammatory Bowel Disease - Pipeline by N30 Pharmaceuticals, H2 2014 95
Inflammatory Bowel Disease - Pipeline by Nogra Pharma Limited, H2 2014 96
Inflammatory Bowel Disease - Pipeline by Novozymes A/S, H2 2014 97
Inflammatory Bowel Disease - Pipeline by Omni Bio Pharmaceutical Inc., H2 2014 98
Inflammatory Bowel Disease - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 99
Inflammatory Bowel Disease - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 100
Inflammatory Bowel Disease - Pipeline by Opsona Therapeutics Ltd., H2 2014 101
Inflammatory Bowel Disease - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 102
Inflammatory Bowel Disease - Pipeline by Pepscan Therapeutics, H2 2014 103
Inflammatory Bowel Disease - Pipeline by ProtAb Ltd, H2 2014 104
Inflammatory Bowel Disease - Pipeline by Protagonist Therapeutics Inc., H2 2014 105
Inflammatory Bowel Disease - Pipeline by RaQualia Pharma Inc., H2 2014 106
Inflammatory Bowel Disease - Pipeline by ReveraGen BioPharma, Inc., H2 2014 107
Inflammatory Bowel Disease - Pipeline by Rottapharm SpA, H2 2014 108
Inflammatory Bowel Disease - Pipeline by Salix Pharmaceuticals Ltd., H2 2014 109
Inflammatory Bowel Disease - Pipeline by Saniona AB, H2 2014 110
Inflammatory Bowel Disease - Pipeline by Sanofi, H2 2014 111
Inflammatory Bowel Disease - Pipeline by Sareum Holdings plc, H2 2014 112
Inflammatory Bowel Disease - Pipeline by Sigmoid Pharma Limited, H2 2014 113
Inflammatory Bowel Disease - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 114
Inflammatory Bowel Disease - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2014 115
Inflammatory Bowel Disease - Pipeline by Synovo GmbH, H2 2014 116
Inflammatory Bowel Disease - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 117
Inflammatory Bowel Disease - Pipeline by TiGenix NV, H2 2014 118
Inflammatory Bowel Disease - Pipeline by Torrent Pharmaceuticals Limited, H2 2014 119
Inflammatory Bowel Disease - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 120
Inflammatory Bowel Disease - Pipeline by Ventria Bioscience, H2 2014 121
Inflammatory Bowel Disease - Pipeline by Zealand Pharma A/S, H2 2014 122
Assessment by Monotherapy Products, H2 2014 123
Assessment by Combination Products, H2 2014 124
Number of Products by Stage and Target, H2 2014 126
Number of Products by Stage and Mechanism of Action, H2 2014 130
Number of Products by Stage and Route of Administration, H2 2014 134
Number of Products by Stage and Molecule Type, H2 2014 136
Inflammatory Bowel Disease Therapeutics - Recent Pipeline Updates, H2 2014 304
Inflammatory Bowel Disease - Dormant Projects, H2 2014 332
Inflammatory Bowel Disease - Dormant Projects (Contd..1), H2 2014 333
Inflammatory Bowel Disease - Dormant Projects (Contd..2), H2 2014 334
Inflammatory Bowel Disease - Dormant Projects (Contd..3), H2 2014 335
Inflammatory Bowel Disease - Dormant Projects (Contd..4), H2 2014 336
Inflammatory Bowel Disease - Dormant Projects (Contd..5), H2 2014 337
Inflammatory Bowel Disease - Dormant Projects (Contd..6), H2 2014 338
Inflammatory Bowel Disease - Dormant Projects (Contd..7), H2 2014 339
Inflammatory Bowel Disease - Dormant Projects (Contd..8), H2 2014 340
Inflammatory Bowel Disease - Discontinued Products, H2 2014 341

[List of Figures]
Number of Products under Development for Inflammatory Bowel Disease, H2 2014 24
Number of Products under Development for Inflammatory Bowel Disease - Comparative Analysis, H2 2014 25
Number of Products under Development by Companies, H2 2014 26
Number of Products under Investigation by Universities/Institutes, H2 2014 34
Comparative Analysis by Clinical Stage Development, H2 2014 36
Comparative Analysis by Early Stage Products, H2 2014 37
Assessment by Monotherapy Products, H2 2014 123
Number of Products by Top 10 Targets, H2 2014 125
Number of Products by Stage and Top 10 Targets, H2 2014 125
Number of Products by Top 10 Mechanism of Actions, H2 2014 129
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 129
Number of Products by Top 10 Routes of Administration, H2 2014 133
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 134
Number of Products by Top 10 Molecule Types, H2 2014 135
Number of Products by Stage and Top 10 Molecule Types, H2 2014 135

【掲載企業】

4SC AG
ActogeniX NV
Addex Therapeutics Ltd
Advinus Therapeutics Ltd.
Aerpio Therapeutics, Inc.
AlbireoPharma
Am-Pharma B.V.
Amakem NV
Amgen Inc.
Amorepacific Corporation
Aquinox Pharmaceuticals Inc.
Ardelyx, Inc.
Argos Therapeutics, Inc.
ASKA Pharmaceutical Co., Ltd.
Axxam SpA
Basilea Pharmaceutica AG
BioLineRx, Ltd.
Biotec Pharmacon ASA
BioTherapeutics Inc.
Blueberry Therapeutics Ltd
Catabasis Pharmaceuticals, Inc.
Celsus Therapeutics Plc
ChemoCentryx, Inc.
ChironWells GmbH
Compugen Ltd.
Cosmo Pharmaceuticals S.p.A
Creabilis SA
Delenex Therapeutics AG
Eisai Co., Ltd.
Emergent BioSolutions Inc.
Galapagos NV
Genentech, Inc.
Genfit SA
GlaxoSmithKline plc
GlycoMar Limited
iCo Therapeutics Inc.
Inotek Pharmaceuticals Corporation
Janssen Biotech, Inc.
Kineta, Inc.
Kymab Limited
Kyorin Pharmaceutical Co., Ltd.
Kytogenics Pharmaceuticals, Inc.
Lumosa Therapeutics Co., Ltd.
Lycera Corp.
Medestea Research & Production S.p.A.
Medgenics Inc.
Mitsubishi Tanabe Pharma Corporation
N30 Pharmaceuticals
Nogra Pharma Limited
Novozymes A/S
Omni Bio Pharmaceutical Inc.
Ono Pharmaceutical Co., Ltd.
Onyx Pharmaceuticals, Inc.
Opsona Therapeutics Ltd.
Paratek Pharmaceuticals, Inc.
Pepscan Therapeutics
ProtAb Ltd
Protagonist Therapeutics Inc.
RaQualia Pharma Inc.
ReveraGen BioPharma, Inc.
Rottapharm SpA
Salix Pharmaceuticals Ltd.
Saniona AB
Sanofi
Sareum Holdings plc
Sigmoid Pharma Limited
SK Biopharmaceuticals Co., Ltd.
Sucampo Pharmaceuticals, Inc.
Synovo GmbH
Takeda Pharmaceutical Company Limited
Theralogics, Inc.
TiGenix NV
Torrent Pharmaceuticals Limited
Upsher-Smith Laboratories, Inc.
Ventria Bioscience
Zealand Pharma A/S

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[炎症性腸疾患(Inflammatory Bowel Disease):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆